AKTX Akari Therapeutics Plc

1.86
-0.04  -2%
Previous Close 1.9
Open 1.88
Price To Book 12.4
Market Cap 39,078,207
Shares 21,008,659
Volume 44,929
Short Ratio
Av. Daily Volume 344,086
Stock charts supplied by TradingView

NewsSee all news

  1. Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting

    Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from

  2. Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    -  New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for either disease. - 

  3. Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

    Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported findingThese new findings suggest that inhibition of both LTB4

  4. Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

    Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients– No reported drug-related serious adverse events– Achieved marked

  5. Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

    NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 staged readouts - no definitive timeline set by company. 2020?
Coversin - CAPSTONE
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 Part B data due 1Q 2020.
Coversin
Atopic keratoconjunctivitis
Phase 2 data presented at EADV Congress with a pivotal trial to commence 2H 2020.
Coversin
Bullous Pemphigoid
Phase 3 trial to commence by end of 2019.
Coversin
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)

Latest News

  1. Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting

    Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from

  2. Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    -  New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for either disease. - 

  3. Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

    Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported findingThese new findings suggest that inhibition of both LTB4

  4. Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

    Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients– No reported drug-related serious adverse events– Achieved marked

  5. Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

    NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  6. Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

    NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  7. Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

    NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  8. Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co?

    NEW YORK, Aug. 30, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, BIG, CPB, and DIS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  9. Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

    NEW YORK and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  10. Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    - Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019Phase I/II clinical study in patients with